Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Personen
Suche
EN
Zurück
Poster session
PoS 1
ePoster 03
Termin
Datum:
06.12.2023
Zeit:
19:30
–
21:00
Ort / Stream:
Industry hall
Chair
Mark Braschinsky
Tartu , EE
Programm
ePoster
P036
Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
Simona Sacco (L'Aquila AQ, IT)
ePoster
P037
Optimizing prophylactic therapy: withdrawal strategies for medication overuse headache in migraine
Alikhan Uzhakhov (Astana, KZ)
ePoster
P038
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
Aaron Jenkins (Tadworth, GB)
ePoster
P039
Effectiveness and tolerability of monoclonal antibodies targeting CGRP pathway for migraine prevention: Real-world data from the Migraine Registry (ReMig) in the Czech Republic
Tomáš Nežádal (Praha 6, CZ)
ePoster
P040
Fremanezumab effectiveness and tolerability in clinical routine: interim real-world-data of the observational FINESSE study
Andreas Straube (Munich, DE)
ePoster
P041
A prospective, observational study to evaluate the long-term safety, including cardiovascular safety, of fremanezumab in patients with migraine in routine clinical practice
Hasan Akcicek (Amsterdam, DE)
ePoster
P042
Efficacy of fremanezumab in reducing Monthly Migraine Days (MMD) and depression severity in patients from european countries with Migraine and Major Depressive Disorder (MDD)
Cristina Tassorelli (Pavia, IT)
ePoster
P043
The possible role of onabotulinum toxin A in the preventive treatment of chronic migraine during pregnancy
Catarina Fernandes (Coimbra, PT)
ePoster
P044
The impact in migraine postdrome phase of monoclonal antibody therapy against CGRP
Catarina Fernandes (Coimbra, PT)
ePoster
P045
Effect of atogepant on the migraine disability assessment, work productivity and activity impairment questionnaire, and patient global impression of change: results from the ELEVATE trial
Pranav Gandhi (Madison, US)
ePoster
P046
Real-life study of migraine burden modification with Botulinum toxin type A introduction in a group I hospital centre in Portugal
Andressa S. Pereira (Chaves, PT)
ePoster
P047
Erenumab 70mg every 15 days: avoiding the "wearing-off" effect in the treatment of pharmacorresistent chronic migraine
Isabel María Lucas Requena (Elche, ES)
ePoster
P048
Patient responses to atogepant 60 mg once daily: a p
ost hoc
analysis of the ADVANCE trial
Peter J. Goadsby (London, GB)
ePoster
P049
Evaluation of rimegepant utilization patterns for acute and preventive treatment of migraine in a commercially insured population
Joshua Brown (New York, US)
ePoster
P050
The impact of fremanezumab treatment on depression severity in patients with concomitant antidepressant use: post hoc analysis of the UNITE study
Piero Barbanti (Rome, IT)
ePoster
P051
Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
Pranav Gandhi (Madison, US)
ePoster
P052
Efficacy of botulinum toxin type A in high frequency episodic migraine: a preliminary study
Beatriz Medeiros (Porto, PT)
ePoster
P053
How does chronic migraine change during three one-year cycles of CGRP-targeting monoclonal antibodies? A real-life study
Gloria Vaghi (Pavia, IT)
ePoster
LP006
OnabotulinmtoxinA as a promising treatment for primary trochlear headache: a case series
Alex Jaimes (Madrid, ES)
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz